This course is designed for medical radiation technologists (MRTs) who want to deepen their understanding of nuclear theranostic procedures and the role of PET/CT in the treatment planning and dosimetry monitoring of these patients.

The course covers the different therapy procedures currently being delivered for neuroendocrine tumours, prostate cancer, leukemia and bone metastasis. It builds on the MRT’s foundational knowledge of radiation emission and detection and explores the fundamental aspects of alpha and beta emitters for treating disease with molecular targeted therapy.

By the end of the course, learners will better understand important procedural aspects of nuclear theranostic procedures and the radiopharmaceuticals used in both the imaging and therapy delivery, aiming to improve the technical quality of imaging studies, understanding of patient dosimetry and enhance patient care quality.

Upon successful completion of this course, learners will be able to:

• Review the different isotopes and commonly used radiopharmaceuticals in nuclear theranostics
• Employ best practices for theranostic radiation safety of patients and technologists within the regulatory requirements of the CNSC
• Express the clinical value and basic principles of theranostic treatment of neuroendocrine, prostate, and other diseases
• Explain the physics involved in the theranostic dosimetry and management of disease
• Explore current evidence and trends related to theranostic approaches in individualized disease management